Adverts

Open Access Articles- Top Results for Serlopitant

Serlopitant

</th></tr>
Serlopitant
File:Serlopitant structure.png
Systematic (IUPAC) name
3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one
Clinical data
Oral
Identifiers
860642-69-9
None
PubChem CID 23653789
Chemical data
Formula C29H28F7NO2
555.527 g/mol

Serlopitant (VPD-737) is a drug which acts as an NK1 receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development.[1][2]

See also

References

  1. ^ Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol. 2010 Aug;184(2):616-22. doi: 10.1016/j.juro.2010.03.147 PMID 20639026
  2. ^ Payton S. Urinary incontinence: Neurokinin receptor antagonist inferior to tolterodine for OAB. Nature Reviews Urology 2010; 7:418. doi:10.1038/nrurol.2010.105



Lua error in package.lua at line 80: module 'Module:Buffer' not found.